54738-73-7

Basic information

• Product Name: 3-BROMO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL
• Synonyms: 3-bromo-1H-indazol-4-ol;3-broMo-1H,4H,5H-pyrazolo[3,4-d]pyriMidin-4-one;3-BroMo-1H-pyrazolo[3,4-d]pyriMidin-4(5H)-one;3-Bromo-4-hydroxypyrazolo[3,4-d]pyrimidine;3-Bromoallopurinol;NSC 344532;3-BROMO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL;3-Bromo-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
• CAS NO: 54738-73-7
• Molecular Formula: C₅H₃BrN₄O
• Molecular Weight: 215.01
• EINECS: 205-525-8
• Mol File: 54738-73-7.mol
• Article Data: 4

Chemical Properties

• Melting Point: 350℃
• Boiling Point: 473.096 °C at 760 mmHg
• Flash Point: 239.92 °C
• Appearance: /
• Density: 2.236 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.834
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 8.16±0.70(Predicted)
• CAS DataBase Reference: 3-BROMO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL(54738-73-7)
• EPA Substance Registry System: 3-BROMO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL(54738-73-7)

Safety Data

• Hazardous Substances Data: 54738-73-7(Hazardous Substances Data)

Usage

General Description

3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-ol is a chemical compound belonging to the class of organic compounds known as pyrazolopyrimidines. These are compounds containing a pyrazolopyrimidine moiety, which consists of a pyrazole ring fused to a pyrimidine ring. The chemical structure of 3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-ol involves a halogen element (bromine), and a functional group containing a hydroxy (-OH) group, implying alcohol properties. 3-BROMO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-OL plays a significant role in various chemical and biochemical research studies due to its unique structure and reactivity.

InChI:InChI=1/C5H3BrN4O/c6-3-2-4(10-9-3)7-1-8-5(2)11/h1H,(H2,7,8,9,10,11)

Upstream product

• 315-30-0 Allopurinol 
• 5399-92-8 4-chloro-1H-pyrazolo[3,4-d]pyrimidine 
• 315-30-0 4-hydroxypyrazolo(3,4-d)pyrimidine 

Downstream Products

• 14246-71-0 3-phenyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 90914-30-0 3-bromo-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-pyrazolo<3,4-d>pyrimidin-4(5H)-one 

Relevant articles and documents

TRIAZOLONE COMPOUNDS AS PERK INHIBITORS

The invention is directed to substituted triazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, X, Y, Y1, and Z are as defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Pyrazolopyrimidines as therapeutic agents

The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R2, and R3 are defined as described herein.